Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00336557 · ClinicalTrials.gov registry record
Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy
A clinical trial, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- 1,230
- Enrollment target
NCT00336557 is a clinical trial that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 1,230 participants.
The verdict
NCT00336557 has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- 1,230 participants
- Enrollment target
Study Summary
An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
Interventions
- PROCEDURE NAbs testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,230 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00336557
The ClinicalTrials.gov registry entry for NCT00336557 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NAbs testing is the first listed.
NCT00336557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00336557 about?
NCT00336557 is a clinical study titled "Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy". An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
What is the current status of trial NCT00336557?
This trial is currently completed. The enrollment target is 1,230 participants. The study started on 2006-07. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00336557?
The interventions under investigation include: NAbs testing (PROCEDURE).
Who is sponsoring clinical trial NCT00336557?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.